IMMUNOCORE HOLDINGS PLC - AMERICAN DEPOSITARY SHAR

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

10 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

02 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

23 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

17 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

03 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore reports third quarter financial results and provides a business update

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

14 Sep 2024 03:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 2024 Cantor Global Healthcare Conference

12 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Immunocore announces transition of Chief Financial Officer

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore reports second quarter financial results and provides a business update

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

01 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

01 Jun 2024 07:59:59 By Nasdaq GlobeNewswire

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

31 May 2024 16:05:00 By Nasdaq GlobeNewswire

Immunocore to present at the Jefferies Global Healthcare Conference

30 May 2024 16:00:00 By Nasdaq GlobeNewswire

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Immunocore reports first quarter financial results and provides a business update

08 May 2024 07:00:00 By Nasdaq GlobeNewswire